Psychedelics

Fluorinated Psilocin Derivative Cuts Psychedelic Effects 75% While Preserving Antidepressant Activity

by

TL;DR: Chemists designed a new psilocin derivative with fluorine modifications that induces sub-hallucinogenic effects in mice, sidestepping the acute psychological effects of classic psychedelics while retaining therapeutic serotonin receptor activity. Psilocybin has emerged as a clinical darling—mounting evidence shows rapid relief for depression, anxiety, and cluster headaches. But there’s a catch: the intense hallucinations and …

Read more

Psychedelics Double 5-Hz Brain Oscillations in Visual Cortex to Produce Hallucinations

by

TL;DR: A psychedelic drug that activates serotonin receptors dramatically amplifies slow 5-Hz brain oscillations in visual and memory regions, suggesting a mechanism for how hallucinogens distort perception by letting internal signals override external reality. Visual perception feels stable, seamless, continuous. But that stability is an illusion orchestrated by your brain. What neuroscientists have long wondered …

Read more

Ketamine Rapidly Reverses Suicidal Ideation & Severe Depression (2024 Meta-Analysis)

by

Ketamine significantly reduces suicidal ideation in depressed patients, with rapid effects observed within the first day of treatment. Highlights: Rapid Reduction: Ketamine shows a significant reduction in suicidal ideation within the first day of treatment (RR = 10.02, 95% CI = 4.24 to 23.68). Sustained Improvement: Repeated ketamine treatments result in a greater reduction of …

Read more

Ketamine Alters Sleep Architecture in Depression: Delta Waves, Alpha Waves, Beta Waves (2024 Study)

by

A study examined the effects of ketamine on sleep arousal metrics in individuals with treatment-resistant depression (TRD) vs. healthy volunteers, finding that ketamine increases certain sleep-related brain activities but does not significantly mediate its antidepressant effects through these sleep changes. Highlights: Individuals with TRD had lower total sleep time and shorter REM latency compared to …

Read more

LSD Linked to Lower Psychological Resilience & Increased Distress After Job Loss (2024 Study)

by

TLDR: LSD does not provide psychological resilience during stressful experiences such as job loss – and may increase psychological distress. Highlights: The study analyzed data from 5,067,553 unemployed individuals seeking jobs. LSD users who had used the drug more than a year before job loss were the focus to ensure accurate results. LSD use prior …

Read more

Ketamine’s Long-Lasting Antidepressant Effects via “Trapping” in NMDA Receptors & LHb

by

Researchers uncover a surprising molecular mechanism that explains ketamine’s exceptionally long-lasting antidepressant effects. Key Facts: Ketamine’s antidepressant effects last for days after its concentration drops to low, ineffective levels only an hour after administration. This contrasts starkly with ketamine’s short 13-minute half-life in the body. Ketamine continues blocking NMDA receptors and suppressing activity in the …

Read more

Psychoplastogens: Rewiring the Brain via Neuroplasticity with Psychedelics

by

Big picture: Psychoplastogens are a groundbreaking new class of psychoactive compounds that rapidly induce structural and functional changes in the brain, allowing pathological neural circuits to be rewired for therapeutic benefit. Key facts about psychoplastogens: Rapidly increase neural plasticity, unlike traditional antidepressants that work slowly. Produce fast-acting and sustained antidepressant effects in humans after a …

Read more

Ibogaine for Opioid Addiction: Safety Concerns & Cardiac Risks

by

Ibogaine, an alkaloid derived from the Tabernanthe iboga shrub found in Africa, has received attention as a potential treatment for addiction, particularly opioid use disorder. While small studies have hinted at effectiveness, a new clinical study shows ibogaine comes with concerning safety risks that may limit its therapeutic potential. Key facts: Ibogaine resulted in significant …

Read more

Ayahuasca: A Potential Treatment for Addiction & Psychiatric Disorders?

by

Ayahuasca is a traditional psychedelic brew from the Amazon that has been used for centuries in shamanic healing rituals. Research is now exploring its potential therapeutic benefits for mental health and addiction. Key Facts: Ayahuasca contains DMT, a hallucinogenic compound, along with MAOIs from the vine Banisteriopsis caapi. The MAOIs allow the DMT to be …

Read more

Psilocybin’s Rapid Anti-Inflammatory Effects (TNF-Alpha, IL-6, CRP) for Depression & Social Benefits

by

A new study provides evidence that the psychedelic compound psilocybin has both immediate and lasting anti-inflammatory effects in healthy volunteers. The findings shed light on how psilocybin may improve mood, social behavior, and potentially treat depression. Key facts: Psilocybin decreased the inflammatory marker TNF-alpha immediately after administration. Seven days later, psilocybin reduced two other inflammatory …

Read more

+ Load more